/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

WAVE LIFE SCIENCES LTD Share Price Today: Live Updates & Key Insights

WAVE LIFE SCIENCES LTD share price today is $13.35, up -5.18%. The stock opened at $13.71 against the previous close of $14.08, with an intraday high of $13.775 and low of $13.22.

WAVE LIFE SCIENCES LTD Share Price Chart

style
pb-0

WAVE LIFE SCIENCES LTD

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

WAVE LIFE SCIENCES LTD Share Price Performance

$13.35 -0.0518(-5.18%) WVE at 13 Mar 2026 03:55 PM Biotechnology
Lowest Today 13.22
Highest Today 13.775
Today’s Open 13.71
Prev. Close 14.08
52 Week High 21.73
52 Week Low 5.28
Day’s Range: Low 13.22 High 13.775
52-Week Range: Low 5.28 High 21.73
1 day return -
1 Week return +1.75
1 month return +5.36
3 month return -17.13
6 month return +91.53
1 year return +29.73
3 year return +230.44
5 year return +32.96
10 year return -

WAVE LIFE SCIENCES LTD Institutional Holdings

RA Capital Management, LLC 9.67

FMR Inc 8.04

BlackRock Inc 5.54

Adage Capital Partners Gp LLC 5.20

Maverick Capital Ltd 4.46

Driehaus Capital Management LLC 3.50

M28 Capital Management LP 3.01

PRIMECAP Management Company 2.18

BB Biotech AG Ord 2.18

T. Rowe Price Associates, Inc. 2.15

683 Capital Management LLC 2.13

Federated Hermes Inc 1.99

Vanguard Group Inc 1.90

PRIMECAP Odyssey Aggressive Growth 1.89

Fidelity Select Health Care 1.59

Geode Capital Management, LLC 1.55

State Street Corp 1.51

iShares Russell 2000 ETF 1.50

Federated Hermes Kaufmann Growth 1.49

Federated Hermes Kaufmann R 1.49

Affinity Asset Advisors, LLC 1.43

Emerald Advisers, LLC 1.30

Siren, L.L.C. 1.30

US Small-Cap Growth II Equity Comp 1.22

T. Rowe Price New Horizons 1.21

Kynam Capital Management, LP 1.15

The Goldman Sachs Group Inc 1.13

Loomis, Sayles & Company LP 1.08

Federated Hermes Kaufmann Small Cap A 0.99

Federated Hermes Kaufmann Small Cap Grow 0.99

Fidelity Growth Compy Commingled Pl S 0.99

Vanguard Institutional Extnd Mkt Idx Tr 0.83

Fidelity Growth Company Fund 0.82

Fidelity Advisor Health Care I 0.82

T. Rowe Price Health Sciences 0.79

T. Rowe Price Integrated US Sm Gr Eq 0.75

Fidelity Small Cap Growth 0.73

Strategic Advisers Fidelity US TtlStk 0.68

T. Rowe Price Integrated US SmCapGrEq 0.61

Fidelity Small Cap Index 0.60

WAVE LIFE SCIENCES LTD Market Status

Strong Buy: 9

Buy: 3

Hold: 1

Sell: 0

Strong Sell: 0

WAVE LIFE SCIENCES LTD Fundamentals

Market Cap 2650.63 M

PB Ratio 4.9937

PE Ratio 0.0

Enterprise Value 2004.20 M

Total Assets 638.50 M

Volume 1814003

WAVE LIFE SCIENCES LTD Company Financials

Annual Revenue FY23:85488000 85.5M, FY22:3649000 3.6M, FY21:40964000 41.0M, FY20:20077000 20.1M, FY19:15983000 16.0M

Annual Profit FY23:null 0.0M, FY22:3649000 3.6M, FY21:40964000 41.0M, FY20:20077000 20.1M, FY19:15983000 16.0M

Annual Net worth FY23:-84966000 -85.0M, FY22:-161823000 -161.8M, FY21:-122245000 -122.2M, FY20:-149910000 -149.9M, FY19:-179496000 -179.5M

Quarterly Revenue Q3/2025:7608000 7.6M, Q2/2025:8699000 8.7M, Q1/2025:9175000 9.2M, Q3/2024:-7676000 -7.7M, Q2/2024:19692000 19.7M

Quarterly Profit Q3/2025:7608000 7.6M, Q2/2025:6503000 6.5M, Q1/2025:7011000 7.0M, Q3/2024:-7676000 -7.7M, Q2/2024:-20701000 -20.7M

Quarterly Net worth Q3/2025:-53852000 -53.9M, Q2/2025:-50469000 -50.5M, Q1/2025:-46878000 -46.9M, Q3/2024:-61780000 -61.8M, Q2/2024:-32923000 -32.9M

About WAVE LIFE SCIENCES LTD & investment objective

Company Information Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.

Organisation Biotechnology

Employees 317

Industry Biotechnology

CEO Dr. Paul B. Bolno M.B.A., M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow